Scholar Rock Holding Corporation Common Stock
SRRK
$51.51
+7.02%
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of rare, severe, and debilitating neuromuscular diseases, with a lead program targeting Spinal Muscular Atrophy (SMA). The company operates as a niche biotech player, distinguishing itself through a proprietary platform targeting the activation of latent growth factors, specifically myostatin, to address muscle atrophy. The current investor narrative is overwhelmingly centered on the clinical and regulatory progress of its lead candidate, apitegromab, as evidenced by the stock's significant price surge in late 2025 and subsequent consolidation, reflecting anticipation of pivotal data readouts, potential partnership deals, and the pathway to commercialization in a competitive SMA treatment landscape.…
SRRK
Scholar Rock Holding Corporation Common Stock
$51.51
SRRK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Scholar Rock Holding Corporation Common Stock's 12-month outlook, with a consensus price target around $66.96 and implied upside of +30.0% versus the current price.
Average Target
$66.96
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$41 - $67
Analyst target range
Analyst coverage for SRRK is limited but consistent, with 5 firms providing estimates. The consensus sentiment is strongly bullish, as reflected in the institutional ratings data showing recent reaffirmations of 'Buy', 'Overweight', and 'Outperform' ratings from firms including JP Morgan, Citigroup, and Barclays in March 2026. The average revenue estimate for the forward period is $843.13 million, with a wide range from $499.23 million to $1.61 billion, indicating high uncertainty around the commercial potential and timing of its lead asset's launch. The average EPS estimate is $1.44, spanning from $0.67 to $3.13. While a specific average price target is not provided in the data, the tight clustering of recent bullish analyst actions and the substantial revenue estimates imply significant implied upside is embedded in analyst models, contingent on successful clinical and regulatory outcomes. The wide range between the low and high revenue estimates signals high uncertainty typical of clinical-stage biotechs; the high-end estimate assumes robust market adoption and strong efficacy, while the low-end likely factors in commercialization risks or competitive pressures.
Bulls vs Bears: SRRK Investment Factors
The bull case for SRRK is powerful but narrow, built entirely on the clinical success and future commercialization of its lead drug candidate, apitegromab, which is reflected in the stock's strong long-term price trend and unanimous analyst support. The bear case, however, presents a formidable counter-argument centered on an extreme valuation that leaves no margin for error, persistent high cash burn, and recent technical weakness suggesting a consolidation after a massive run-up. Currently, the bear side holds stronger near-term evidence due to the stock's extreme valuation (PB of 20.58) and its recent significant underperformance versus the market. The single most important tension in the investment debate is whether apitegromab's clinical and commercial potential can justify and sustain a valuation that has already expanded tenfold, or if the current price represents a peak in optimism vulnerable to any negative development.
Bullish
- Strong Clinical Pipeline Momentum: The stock's 56.55% surge over the past six months and its proximity to 52-week highs reflect intense market anticipation for the lead candidate, apitegromab, in Spinal Muscular Atrophy (SMA). This momentum is underpinned by a proprietary platform targeting latent myostatin, a novel mechanism in a high-value therapeutic area.
- Substantial Cash Runway: With $327.33 million in cash and equivalents and a robust current ratio of 6.95, Scholar Rock has a significant financial cushion to fund its clinical programs. The quarterly net loss improved from -$110.03M in Q2 2025 to -$90.97M in Q4 2025, suggesting a moderating cash burn rate as trials progress.
- Unanimous Analyst Bullishness: Analyst consensus is strongly positive, with recent 'Buy' and 'Overweight' reaffirmations from major firms like JP Morgan and Barclays in March 2026. The average forward revenue estimate of $843.13 million, despite a wide range, signals high conviction in the commercial potential of apitegromab upon successful approval.
- Favorable Relative Strength Trend: The stock exhibits a 12-month relative strength of +12.50 against the SPY, indicating it has outperformed the broader market over the past year. This long-term outperformance suggests sustained investor confidence in the company's clinical progress and future prospects.
Bearish
- Extreme Valuation on Historical Basis: The Price-to-Book ratio has ballooned from ~1.80 in 2022 to 20.58, a more than 10-fold expansion. This places the stock at the very top of its historical valuation range, indicating that immense success for apitegromab is already priced in, leaving minimal room for error.
- No Revenue and Deep Cash Burn: The company is pre-revenue with quarterly revenue of $0 and a trailing twelve-month free cash flow of -$300.64 million. The quarterly operating cash flow of -$75.50 million demonstrates a heavy reliance on its cash balance, necessitating future dilutive financing if commercialization is delayed.
- High Short Interest and Recent Weakness: A short ratio of 8.15 indicates significant speculative bets against the stock. This is corroborated by recent price action: a -6.04% return over the past month against a +9.98% SPY return, resulting in a stark -16.02 relative strength, signaling profit-taking and waning short-term momentum.
- Binary Clinical & Regulatory Risk: The entire investment thesis hinges on the success of apitegromab in a competitive SMA landscape. The wide analyst revenue estimate range ($499M to $1.61B) underscores the extreme uncertainty. Any clinical setback or regulatory delay could trigger a severe re-rating from current elevated levels.
SRRK Technical Analysis
The stock is in a sustained, powerful uptrend over the past year, evidenced by a 1-year price change of +41.54% and a 6-month surge of +56.55%. With a current price of $46.37, it is trading at approximately 74% of its 52-week range ($27.07 to $51.625), positioning it closer to recent highs but not at the absolute peak, suggesting retained momentum without extreme overextension. Recent momentum, however, shows signs of consolidation and short-term weakness, with the stock down -6.04% over the past month, diverging negatively from the strong yearly trend. This 1-month pullback, occurring against a market (SPY) that was up +9.98%, resulted in a stark relative strength reading of -16.02, indicating significant underperformance and potential profit-taking or sector rotation after the prior explosive move. Key technical levels are clearly defined by the 52-week low of $27.07 and high of $51.625; a decisive breakout above $51.63 would signal a resumption of the primary bull trend, while a breakdown below the $40 support area (tested in March 2026) could indicate a deeper correction. The stock's beta of 0.687 suggests it has been less volatile than the broader market historically, though the recent price action and a high short ratio of 8.15 point to elevated speculative interest and potential for sharp moves on news.
Beta
0.71
0.71x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$27-$52
Price range past year
Annual Return
+71.7%
Cumulative gain past year
| Period | SRRK Return | S&P 500 |
|---|---|---|
| 1m | +10.8% | +5.1% |
| 3m | +9.7% | +8.3% |
| 6m | +19.4% | +10.4% |
| 1y | +71.7% | +29.6% |
| ytd | +20.4% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SRRK Fundamental Analysis
Scholar Rock is a pre-revenue company, with quarterly revenue consistently reported as $0, reflecting its clinical-stage status where investment is entirely focused on research and development. The growth trajectory is purely pipeline-driven, with the most recent quarterly net loss of -$90.97 million in Q4 2025 representing the cost of advancing its clinical programs. The company is deeply unprofitable, with a trailing EPS of -$0.07 and a net income margin of 0%; however, examining the trend, the quarterly net loss improved from -$110.03 million in Q2 2025 to -$90.97 million in Q4 2025, suggesting a potential moderation in cash burn as it progresses through clinical trials. Gross profit is negative (-$425k in Q4 2025) due to nominal costs of revenue, which is typical for a biotech without commercial sales, making operating margin analysis irrelevant at this stage. The balance sheet shows a strong liquidity position with a current ratio of 6.95 and cash and equivalents of $327.33 million as of Q4 2025, providing a substantial runway. However, operating and free cash flow are deeply negative, at -$75.50 million and -$75.53 million for the quarter, respectively, indicating heavy reliance on this cash balance and future financing to fund operations, underscored by a trailing twelve-month free cash flow of -$300.64 million and a Return on Equity of -154%.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-300637000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SRRK Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio; however, with current revenue at $0, the PS ratio is not meaningful. Therefore, we must rely on forward-looking estimates or alternative metrics like Enterprise Value-to-EBITDA, which is also negative at -13.10x due to deeply negative EBITDA. The forward PE ratio is -21.65x, which is not a standard valuation tool for a loss-making company but highlights the market is valuing future earnings potential that are still projected to be negative in the near term. Peer comparison using standard multiples is challenging due to the lack of revenue and profits; the valuation is entirely driven by the perceived potential of the clinical pipeline and probability-adjusted future sales, rather than current financial metrics. Historically, the stock's own valuation multiples have expanded dramatically, with its Price-to-Book ratio rising from around 1.80 at the end of 2022 to 20.58 as of Q4 2025. This 10-fold increase in PB ratio places the stock at the very top of its historical valuation range, indicating the market has priced in extremely optimistic expectations for the success of its lead candidate, apitegromab, leaving little margin for clinical or regulatory setbacks.
PE
-13.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -17x~-1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and inherent to SRRK's clinical-stage status. The company generates zero revenue and burns cash at a rate of approximately $75.5 million per quarter, with a trailing twelve-month free cash flow of -$300.64 million. While the $327.33 million cash balance provides a runway, the deeply negative ROE of -154% and net income margin of 0% highlight the complete dependence on external capital and future drug approval for survival. The improvement in quarterly net loss from -$110.03M to -$90.97M is positive but does not alter the fundamental cash-burning nature of the business, which will require additional financing or a lucrative partnership to reach commercialization.
Market & Competitive Risks are dominated by valuation compression. Trading at a Price-to-Book ratio of 20.58—over ten times its 2022 level—the stock is priced for flawless execution. Any clinical hiccup, regulatory delay, or competitive threat in the SMA treatment landscape could trigger a dramatic multiple contraction. The stock's beta of 0.687 is low, but this is misleading for a binary-event stock; its true risk is uncorrelated, company-specific news. The high short ratio of 8.15 signals a sophisticated cohort of investors betting specifically on such a negative catalyst, adding to selling pressure potential.
Worst-Case Scenario involves apitegromab failing a key clinical trial or receiving a complete response letter from regulators. This would immediately invalidate the core investment thesis, leading to a rapid repricing towards the company's liquidation or pipeline reset value. The realistic downside could see the stock retreat to its 52-week low of $27.07, representing a potential loss of approximately -42% from the current price of $46.37. A more severe scenario, factoring in a need for immediate dilutive financing amid shattered confidence, could push the stock even lower, potentially matching the stock's historical max drawdown of -34.86% from a recent peak, which would imply a price in the low $30s.